These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
409 related articles for article (PubMed ID: 34294065)
1. Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature. Meyer N; Cooper W; Kirwan P; Garsia R; Dunkley S; Gracey DM BMC Nephrol; 2021 Jul; 22(1):268. PubMed ID: 34294065 [TBL] [Abstract][Full Text] [Related]
2. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report. Ishiwatari A; Wakai S; Shirakawa H; Honda K Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399 [TBL] [Abstract][Full Text] [Related]
3. Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A Tominaga K; Uchida T; Imakiire T; Itoh K; Shimazaki H; Nakanishi K; Kumagai H; Oshima N BMC Nephrol; 2018 May; 19(1):120. PubMed ID: 29792176 [TBL] [Abstract][Full Text] [Related]
4. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA PLoS One; 2014; 9(10):e110681. PubMed ID: 25313791 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection. Li X; Song D; Hao Y; Ren M; Guo Y; Zhao H; Wang Y; Tang L Sci Rep; 2024 Sep; 14(1):20981. PubMed ID: 39251782 [TBL] [Abstract][Full Text] [Related]
13. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach. Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260 [TBL] [Abstract][Full Text] [Related]